載入...
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
PURPOSE: Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy. PATIENTS AND METHODS: In this randomized phase II trial,...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Artigo |
語言: | Inglês |
出版: |
American Society of Clinical Oncology
2012
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3413275/ https://ncbi.nlm.nih.gov/pubmed/22665533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.5579 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|